lung cancer – Medxy AI

PET/CT-Guided Discontinuation of Immunotherapy in Metastatic Lung Cancer: A Paradigm Shift Toward Precision De-escalation

By MedXY 01/10/2026

A landmark study from the nNGM reveals that PET/CT-guided discontinuation of immunotherapy in long-term lung cancer responders significantly improves survival and identifies second primary cancers, challenging the current practice of indefinite treatment.

Clinical Updates news Oncology

Risk and Outcomes of Secondary Cancer Among Lung Cancer Survivors After Definitive Treatment: A Comprehensive Review

By MedXY 12/13/2025

This review synthesizes evidence on the incidence, risk factors, and outcomes of secondary cancers in non-small cell lung cancer survivors post-definitive therapy, highlighting genetic predisposition as a key determinant distinct from recurrence patterns.

Oncology Psychiatry Specialties

Esketamine in Lung Cancer Patients with Major Depression: Efficacy for Smoking Cessation and Treatment-Resistant Depression

By MedXY 08/25/2025

This review synthesizes evidence from a randomized trial and real-world studies showing esketamine's efficacy and safety in smoking cessation among lung cancer patients with MDD, as well as in treatment-resistant depression, highlighting cognitive benefits and long-term safety.

Clinical Updates news Oncology Specialties

A Century of Change: How Human Innovation Transformed Lung Cancer Treatment

By MedXY 08/03/2025

Lung cancer therapy has evolved from rudimentary surgery and misdiagnosis to a precision medicine era, markedly improving outcomes through targeted therapies and immunotherapy.